Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;12(3):1935-1940.
doi: 10.3892/ol.2016.4871. Epub 2016 Jul 15.

Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences

Daniel Ruiz-Sánchez  1 , Irene Iglesias Peinado  2 , Miguel Alaguero-Calero  3 , Alejandro José Sastre-Heres  4 , Benito García Diez  5 , Jaime Peña-Díaz  6
Affiliations

Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences

Daniel Ruiz-Sánchez et al. Oncol Lett. 2016 Sep.

Abstract

The purpose of the present study was to calculate the cost-effectiveness of the inclusion of the bevacizumab (BVZ) + irinotecan (CPT-11) regimen in the second-line of treatment for primary glioblastoma multiforme. A retrospective cohort study with a control group was performed in which the cost-effectiveness of a course of chemotherapy was calculated based on survival time and the incremental cost between the two lines of treatment. A total of 77 patients were included, 36 of who formed the BVZ/CPT-11 cohort. The median survival time for the non-BVZ control cohort was 13.23 months [95% confidence interval (CI), 11.79-14.68], while for the BVZ/CPT-11 treatment cohort, the median survival time was 17.63 months (95% CI, 15.38-19.89). Overall, each year of life gained for each patient treated with BVZ/CPT-11 would cost €46,401.99. These results demonstrate the effectiveness of the BVZ/CPT-11 combination, but its incremental cost compared with other lines of treatment or the best care available does not appear to be acceptable for public health systems in the current situation of budgetary adjustments.

Keywords: antiangiogenic; bevacizumab; cost-effectiveness; glioblastoma; irinotecan.

PubMed Disclaimer

References

    1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C, Barnholtz-Sloan J. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(Suppl 4):iv1–iv63. doi: 10.1093/neuonc/nou223. - DOI - PMC - PubMed
    1. Gurney JG, Kadan-Lottick N. Brain and other central nervous system tumors: Rates, trends and epidemiology. Curr Opin Oncol. 2001;13:160–166. doi: 10.1097/00001622-200105000-00005. - DOI - PubMed
    1. Fuentes-Raspall R, Vilardell L, Perez-Bueno F, Joly C, Garcia-Gil M, Garcia-Velasco A, Marcos-Gragera R. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005. J Neurooncol. 2011;101:117–123. doi: 10.1007/s11060-010-0240-7. - DOI - PubMed
    1. http://www.hca.es/huca/web/main.asp?id_pagina=29. [Jun 25;2015 ];Tumours register of the health service of the principality of Asturias for 2013. ISSN: 2176-6885. Accessed.
    1. Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, et al. Central nervous system cancers. J Natl Compr Canc Netw. 2011;9:352–400. - PubMed

LinkOut - more resources